Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developing a dynamic pharmacophore model for HIV-1 integrase.

H A Carlson1, K M Masukawa, K Rubins

  • 1Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093-0365, USA. hcarlson@mccammon.ucsd.edu

Journal of Medicinal Chemistry
|June 8, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.

Nature medicine·2022
Same author

Genetic and phenotypic characteristics of Clostridium (Clostridioides) difficile from canine, bovine, and pediatric populations.

Anaerobe·2022
Same author

Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.

Nature medicine·2022
Same author

NWChem: Past, present, and future.

The Journal of chemical physics·2020
Same author

Structure activity relationship towards design of cryptosporidium specific thymidylate synthase inhibitors.

European journal of medicinal chemistry·2019
Same author

RPYFMM: Parallel Adaptive Fast Multipole Method for Rotne-Prager-Yamakawa Tensor in Biomolecular Hydrodynamics Simulations.

Computer physics communications·2018
Same journal

Development of Indole-3-yl-methylene-thiobarbital Derivatives as Inhibitors of HDAC8 Enzyme Activity.

Journal of medicinal chemistry·2026
Same journal

Discovery of a Potent NAMPT-Targeting PROTAC for the Suppression of Triple-Negative Breast Cancer via Macrophage Reprogramming.

Journal of medicinal chemistry·2026
Same journal

3',4'-Isopropylidene-α-galactosylceramide Enables Multidose Th1 Adjuvanticity Despite Limited Serial Serum IFN-γ Responsiveness.

Journal of medicinal chemistry·2026
Same journal

A Bioorthogonally Cleavable <i>N</i>-Oxide Linker for Prodrug Design: Elucidating the Structure-Cyclization Kinetics Relationships for Controlled Drug Release.

Journal of medicinal chemistry·2026
Same journal

A Melatonin-Catechol Hybrid Molecule Prolongs Lifespan via Regulating ROS and Reprogramming Mitochondrial Metabolism.

Journal of medicinal chemistry·2026
Same journal

Discovery of SD-2301 as a Highly Potent and Selective PROTAC STAT3 Degrader Capable of Achieving Complete Tumor Regression with Single Administration.

Journal of medicinal chemistry·2026
See all related articles

We developed a novel dynamic pharmacophore model for HIV-1 integrase, improving drug discovery by accounting for protein flexibility. This model successfully identified new inhibitors, outperforming static models.

Area of Science:

  • Structural Biology
  • Computational Chemistry
  • Drug Discovery

Background:

  • HIV-1 integrase is a key target for antiviral therapy.
  • Existing pharmacophore models often fail due to protein flexibility.
  • Limitations exist with incomplete crystal structures for drug design.

Purpose of the Study:

  • To develop the first receptor-based dynamic pharmacophore model for HIV-1 integrase.
  • To improve drug discovery by incorporating protein flexibility.
  • To identify novel HIV-1 integrase inhibitors.

Main Methods:

  • Utilized molecular dynamics (MD) simulations to capture protein flexibility.
  • Employed multi-unit search for interacting conformers (MUSIC) simulations.
  • Compared dynamic model with static models and known inhibitors.

Related Experiment Videos

Main Results:

  • The dynamic pharmacophore model accurately describes known HIV-1 integrase inhibitors.
  • Static models failed to identify effective inhibitors.
  • Identified and experimentally validated new HIV-1 integrase inhibitors.

Conclusions:

  • Dynamic pharmacophore modeling is a superior approach for HIV-1 integrase inhibitor design.
  • This method overcomes limitations of static models and incomplete structures.
  • The identified compounds represent promising leads for new HIV therapies.